Brazikumab

From WikiMD.org
Jump to navigation Jump to search

Brazikumab

Brazikumab (pronounced brah-zee-koo-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is currently under investigation for its potential use in treating inflammatory bowel disease (IBD) and Crohn's disease.

Etymology

The name "Brazikumab" is derived from the pharmaceutical naming convention for monoclonal antibodies, where "-mab" is used as a suffix. The prefix "Brazi-" does not have a specific meaning and is likely chosen for uniqueness.

Mechanism of Action

Brazikumab works by inhibiting the interleukin-23 (IL-23) pathway, a key player in the immune response and inflammation. By blocking this pathway, Brazikumab can potentially reduce inflammation and alleviate symptoms in patients with autoimmune diseases.

Related Terms

  • Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells. Brazikumab is a type of monoclonal antibody.
  • Autoimmune Disease: A condition in which your immune system mistakenly attacks your body. Brazikumab is being studied for its potential use in treating autoimmune diseases.
  • Inflammatory Bowel Disease (IBD): A term for two conditions (Crohn's disease and ulcerative colitis) that are characterized by chronic inflammation of the gastrointestinal (GI) tract. Brazikumab is currently under investigation for its potential use in treating IBD.
  • Crohn's Disease: A type of inflammatory bowel disease. It causes inflammation of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Brazikumab is currently under investigation for its potential use in treating Crohn's disease.
  • Interleukin-23 (IL-23): A cytokine that plays a key role in the immune response and inflammation. Brazikumab works by inhibiting the IL-23 pathway.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski